1
|
Humbert L, Proust-Lemoine E, Dubucquoi S, Kemp EH, Saugier-Veber P, Fabien N, Raymond-Top I, Cardot-Bauters C, Carel JC, Cartigny M, Chabre O, Chanson P, Delemer B, Do Cao C, Guignat L, Kahn JE, Kerlan V, Lefebvre H, Linglart A, Mallone R, Reynaud R, Sendid B, Souchon PF, Touraine P, Wémeau JL, Vantyghem MC. Lessons from prospective longitudinal follow-up of a French APECED cohort. J Clin Endocrinol Metab 2024:dgae211. [PMID: 38605470 DOI: 10.1210/clinem/dgae211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 03/05/2024] [Accepted: 04/01/2024] [Indexed: 04/13/2024]
Abstract
BACKGROUND APECED syndrome is a rare disease caused by biallelic mutations of the AIRE gene, usually presenting with the triad "hypoparathyroidism-adrenal failure-chronic mucocutaneous candidiasis (CMC)" and non-endocrine manifestations. The aim of this study was to determine the molecular profile of the AIRE gene, the prevalence of rare manifestations and to characterize immunological disturbances in a French cohort. PATIENTS AND METHODS A national, multicenter prospective observational study to collect genetic, clinical, biological and immunological data (NCT03751683). RESULTS 25 patients (23 families) were enrolled. Eleven distinct AIRE variants were identified, two of which were not previously reported: an intronic variant, c.653-70G > A, and a c.1066del (p.Arg356GlyfsX22) variant (exon 9). The most common was the Finnish variant c.769C > T (16 alleles), followed by the variant c.967_979del13 (15 alleles), which seemed associated with a less severe phenotype. 17/25 patients were homozygote. The median number of clinical manifestations was seven; 19/25 patients presented with the hypoparathyroidism-adrenal failure-CMC triad, 8/13 showed pulmonary involvement, 20/25 had ectodermal dystrophy, 8/25 had malabsorption, and 6/23 had asplenia. Fifteen out of 19 patients had NK cell lymphopenia with an increase in CD4+ and CD8+ T lymphocytes and an age-dependent alteration of B lymphocyte homeostasis compared with matched controls (p < 0.001), related to the severity of the disease. All tested sera (n = 18) were positive for anti-interferon-α, 15/18 for anti-interleukin-22 antibodies, and 13/18 for anti-interleukin-17F antibodies, without clear phenotypic correlation other than with CMC. CONCLUSION This first prospective cohort showed a high AIRE genotype variability, with two new gene variants. The prevalence of potentially life-threatening non-endocrine manifestations, was higher with systematic screening. These manifestations could, along with age-dependent B-cell lymphopenia, contribute to disease severity. Systematic screening for all the manifestations of the syndrome would allow earlier diagnosis, supporting vaccination, and targeted therapeutic approaches.
Collapse
Affiliation(s)
- Linda Humbert
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France
| | - Emmanuelle Proust-Lemoine
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France
| | - Sylvain Dubucquoi
- Institut d'Immunologie-HLA, Centre de Biologie-Pathologie, Boulevard du Professeur Jules Leclercq - 59037 Lille Cedex
- University of Lille, F-59000 Lille, France
| | - Elisabeth Helen Kemp
- Department of Oncology and Metabolism, Faculty of Medicine, Dentistry and Health, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, UK
| | - Pascale Saugier-Veber
- Univ Rouen Normandie, Inserm U1245, Normandie Univ and CHU Rouen, Department of Genetics and Reference Center for Developmental Disorders, F-76000 Rouen, France
| | | | - Isabelle Raymond-Top
- Institut d'Immunologie-HLA, Centre de Biologie-Pathologie, Boulevard du Professeur Jules Leclercq - 59037 Lille Cedex
| | - Catherine Cardot-Bauters
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France
| | - Jean-Claude Carel
- AP-HP Nord Université Paris Cité, Hôpital Universitaire Robert-Debré, Service d'Endocrinologie Diabétologie Pédiatrique & INSERM NeuroDiderot, Centre de Référence Maladies Endocriniennes Rares de la Croissance, 48, Boulevard Sérurier, 75935 Paris cedex 19, France
| | - Maryse Cartigny
- Department of Pediatry, Hôpital Jeanne de Flandres, Lille University Hospital, F-59000 Lille, France
| | - Olivier Chabre
- Univ. Grenoble Alpes, Service d'Endocrinologie CHU Grenoble Alpes, Unité mixte de recherche INSERM-CEA-UGA UMR1036 38000 Grenoble Alpes
| | - Philippe Chanson
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Brigitte Delemer
- Department of Endocrinology and Diabetology, CHU Reims, 45 Rue Cognacq Jay, 51 092 Reims, France
| | - Christine Do Cao
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France
| | - Laurence Guignat
- Centre de Référence des Maladies Rares de la Surrénale, Endocrinologie, Hôpital Cochin, 123, Boulevard de Port Royal, 75014 Paris, France
| | - Jean Emmanuel Kahn
- Institut d'Immunologie-HLA, Centre de Biologie-Pathologie, Boulevard du Professeur Jules Leclercq - 59037 Lille Cedex
- Department of Internal Medicine, National Reference Center for Hypereosinophilic Syndromes (CEREO), Hôpital Foch, 40, Rue Worth, 92151, Suresnes, France and University of Paris Saclay, APHP, CHU Ambroise Paré, Boulogne-Billancourt, France
| | - Veronique Kerlan
- Department of Endocrinology, Diabetology and Metabolism CHU Brest, Hôpital de la Cavale Blanche, 29609 Brest Cedex France
| | - Herve Lefebvre
- Department of Endocrinology, University Hospital of Rouen, 1, rue de Germont, 76031 Rouen, France
| | - Agnès Linglart
- AP-HP, Service d'Endocrinologie et Diabète de l'Enfant, Hôpital Bicêtre Paris-Saclay, AP-HP, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, Filière OSCAR, ERN BOND, ERN for Rare Endocrine Disorders, Plateforme d'Expertise des Maladies Rares de Paris Saclay, Université Paris Saclay, INSERM U1185, Le Kremlin-Bicêtre, France
| | - Roberto Mallone
- Clinical Department of Diabetology and Clinical Immunology, INSERM U1016 Cochin Institute, DeARLab Team Mallone-You, Groupe Hospitalier Cochin-Port-Royal, Bâtiment Cassini, 123, Boulevard de Port-Royal, 75014 Paris
| | - Rachel Reynaud
- Service de Pediatrie Multidisciplinaire CHU Timone Enfants APHM Aix Marseile Université Centre de Reference Maladies Hypophysaire Rares 13385 Marseille Cedex 05
| | - Boualem Sendid
- Institut de Microbiologie, Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, 1, Boulevard Pr J. Leclercq, 59037 Lille Cedex, Inserm U1285 - CNRS UMR 8576, 1 Place Verdun, 59037 Lille- France
| | - Pierre-François Souchon
- CHU de Reims - American Memorial Hospital - Service de Pédiatrie , 47 rue Cognac Jay, 51092 Reims Cedex, France
| | - Philippe Touraine
- Department of Endocrinology and Reproductive Medicine, AP-HP, Sorbonne University Medicine, 91-105 Bd de l'Hôpital, 75013 Paris France
| | - Jean-Louis Wémeau
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France
- University of Lille, F-59000 Lille, France
| | - Marie-Christine Vantyghem
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France
- University of Lille, F-59000 Lille, France
- Inserm U1190, Lille University, European Genomic Institute for Diabetes, F-59000 Lille, France
| |
Collapse
|
2
|
Benderradji H, Do Cao C, Ladsous M, Wémeau JL. [Exploration and management of thyroid nodules]. Rev Prat 2023; 73:431-437. [PMID: 37289163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
EXPLORATION AND MANAGEMENT OF THYROID NODULES. Most thyroid nodules are benign (95%) and can benefit from clinical and ultrasound monitoring. Cancers (approximately 5% of nodules) could be suspected, particularly in subjects whose neck was irradiated, in cases of a hard, irregular, evolving nodule, or with very high serum calcitonin (> 100 pg/ml). It is crucial to recognize cancers when nodules exceed the supracentimeter stage. Thyroid ultrasonography is the most common, handy, safe, and cost-effective tool to image thyroid nodules. It classifies thyroid nodules according to the EU-TIRADS score, which comprises 5 categories associated with an increasing risk of malignancy. An ultrasound-guided fine needle aspiration (FNA) biopsy is performed only in nodules staged EU-TIRADS classes 5, 4, and 3 over 1, 1.5, and 2 cm, respectively. Cytologic analysis of FNA material classifies thyroid nodules according to the Bethesda system into 6 classes, each with its own prognostic value. The difficulties in cytological evaluation are related to the uninterpretable (Bethesda I) and indeterminate (especially III and IV) results, for which have to be discussed opportunities of reassessment and follow-up by scintiscans and cytological molecular markers. Management is imperfectly codifiable: from surveillance in the absence of suspicious elements initially to total thyroidectomy in their presence.
Collapse
Affiliation(s)
- Hamza Benderradji
- Chef de clinique des universités-assistant des hôpitaux, université de Lille, CHU de Lille
| | | | | | | |
Collapse
|
3
|
Benderradji H, Beron A, Wémeau JL, Carnaille B, Delcroix L, Do Cao C, Baillet C, Huglo D, Lion G, Boury S, Cussac JF, Caiazzo R, Pattou F, Leteurtre E, Vantyghem MC, Ladsous M. Quantitative dual isotope 123iodine/ 99mTc-MIBI scintigraphy: A new approach to rule out malignancy in thyroid nodules. Ann Endocrinol (Paris) 2021; 82:83-91. [PMID: 33727116 DOI: 10.1016/j.ando.2021.03.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 03/07/2021] [Accepted: 03/08/2021] [Indexed: 11/18/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the role of dual isotope 123Iodine/99mTc-MIBI thyroid scintigraphy (IMS) in discriminating between malignant and benign lesions in indeterminate nodules using quantitative analysis methods. METHODS Thirty-five consecutive patients with thyroid nodules of indeterminate or non-diagnostic cytology and cold on 123Iodine scintigraphy (10 Bethesda I, 24 Bethesda III-IV, 1 in which cytology was impossible) underwent IMS between 2017 and 2019 with uptake quantification at two time points ahead of thyroidectomy: early and late. Images were analyzed by two blinded physicians. RESULTS Twelve nodules were malignant and 23 benign on histopathology. Mean uptake values were lower in benign than in malignant nodules at both time points: early, 8.7±4.1 versus 12.9±3.5 (P=0.005); and late, 5.3±2.7 versus 7.7±1.1 (P=0.008). Interobserver reproducibility was excellent. The intraclass correlation coefficient was 0.86 in benign and 0.92 in malignant lesions for early uptake result (ER) and 0.94 and 0.85 respectively for late uptake result (LR). The optimal LR cut-off to exclude a diagnosis of malignancy was set at 5.9 . The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of this cut-off were, respectively, 100%, 65.2%, 60%, 100% and 77.1%. CONCLUSION Despite some study limitations, quantitative analysis of 99mTc-MIBI thyroid scintigraphy had a good reproducibility, which could help to rule out malignancy in non-diagnostic or indeterminate thyroid nodules and thereby reducing the number of patients undergoing unnecessary surgery when LR is below 5.9.
Collapse
Affiliation(s)
- Hamza Benderradji
- Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France; Inserm, U 1172, Lille University, Lille, France.
| | - Amandine Beron
- Department of Nuclear Medicine, Lille University Hospital, Lille, France
| | - Jean-Louis Wémeau
- Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France
| | - Bruno Carnaille
- Department of General and Endocrine Surgery, Lille University Hospital, Lille, France
| | - Laurent Delcroix
- Department of Nuclear Medicine, Lille University Hospital, Lille, France
| | - Christine Do Cao
- Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France
| | - Clio Baillet
- Department of Nuclear Medicine, Lille University Hospital, Lille, France
| | - Damien Huglo
- Department of Nuclear Medicine, Lille University Hospital, Lille, France; Inserm, U 1189, Lille University, Lille, France
| | - Georges Lion
- Department of Nuclear Medicine, Lille University Hospital, Lille, France
| | - Samuel Boury
- Department of Radiology, Lille University Hospital, Lille, France
| | | | - Robert Caiazzo
- Department of General and Endocrine Surgery, Lille University Hospital, Lille, France; Inserm, U1190-EGID, Lille University, Lille, France
| | - François Pattou
- Department of General and Endocrine Surgery, Lille University Hospital, Lille, France; Inserm, U1190-EGID, Lille University, Lille, France
| | - Emmanuelle Leteurtre
- Department of Pathology, Lille University Hospital, Lille, France; Inserm, CNRS, UMR9020, U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille University, Lille, France
| | - Marie-Christine Vantyghem
- Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France; Inserm, U1190-EGID, Lille University, Lille, France
| | - Miriam Ladsous
- Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France; Department of Endocrinology, Valenciennes General Hospital, Valenciennes, France
| |
Collapse
|
4
|
Lehnert H, Castello-Bridoux C, Channaiah B, Martiniere K, Hildemann S, Wémeau JL. Comparison of Safety Profiles of the New and Old Formulations of Levothyroxine in a First Global Introduction in France. Exp Clin Endocrinol Diabetes 2021; 129:908-917. [PMID: 33511579 DOI: 10.1055/a-1302-9343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Levothyroxine sodium marketed in France was reformulated following a French National Agency for Medicines and Health Products Safety request for a more stringent potency specification. Despite previously established purity and bioequivalence of the new and old formulations, reports of adverse events substantially increased following reformulation. This analysis evaluated the nature and relevance of the medically confirmed safety reports. METHODS Spontaneous and solicited individual case safety reports in France were retrieved from 26 March 2015 to 30 June 2016 (old formulation) and 26 March 2017 to 30 June 2018 (new formulation). Rates of reports and adverse events were calculated for the overall patient population and for at-risk subgroups. Adverse events delineated by thyroid-stimulating hormone levels were evaluated. RESULTS A total of 295 and 42 775 reports for the old formulation and new formulation, respectively, were retrieved, with 149 and 5503 medically confirmed. The most common medically confirmed adverse events were consistent with the known safety profile of levothyroxine, with generally comparable rates between both formulations (range of differences, 1.8-4.1%). Most cases were not serious (old formulation, 65.8%; new formulation, 78.7%). Reporting rates were similar or higher for the old formulation within subgroups of at-risk patients. Nature/distributions of adverse events by thyroid-stimulating hormone levels as determined by both the marketing authorization holder of levothyroxine and the French National Agency for Medicines and Health Products Safety were similar. CONCLUSIONS The new formulation safety profile aligns with the established profile of the old formulation of levothyroxine. The benefit-risk profile is unchanged, such that the benefits of using the new formulation in the approved indications outweigh the risks associated with the treatment.
Collapse
Affiliation(s)
- Hendrik Lehnert
- Center of Brain, Behavior and Metabolism, University of Luebeck, Lübeck, Germany.,University of Salzburg, Austria
| | | | | | | | | | | |
Collapse
|
5
|
Groeneweg S, van Geest FS, Abacı A, Alcantud A, Ambegaonkar GP, Armour CM, Bakhtiani P, Barca D, Bertini ES, van Beynum IM, Brunetti-Pierri N, Bugiani M, Cappa M, Cappuccio G, Castellotti B, Castiglioni C, Chatterjee K, de Coo IFM, Coutant R, Craiu D, Crock P, DeGoede C, Demir K, Dica A, Dimitri P, Dolcetta-Capuzzo A, Dremmen MHG, Dubey R, Enderli A, Fairchild J, Gallichan J, George B, Gevers EF, Hackenberg A, Halász Z, Heinrich B, Huynh T, Kłosowska A, van der Knaap MS, van der Knoop MM, Konrad D, Koolen DA, Krude H, Lawson-Yuen A, Lebl J, Linder-Lucht M, Lorea CF, Lourenço CM, Lunsing RJ, Lyons G, Malikova J, Mancilla EE, McGowan A, Mericq V, Lora FM, Moran C, Müller KE, Oliver-Petit I, Paone L, Paul PG, Polak M, Porta F, Poswar FO, Reinauer C, Rozenkova K, Menevse TS, Simm P, Simon A, Singh Y, Spada M, van der Spek J, Stals MAM, Stoupa A, Subramanian GM, Tonduti D, Turan S, den Uil CA, Vanderniet J, van der Walt A, Wémeau JL, Wierzba J, de Wit MCY, Wolf NI, Wurm M, Zibordi F, Zung A, Zwaveling-Soonawala N, Visser WE. Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol 2020; 8:594-605. [PMID: 32559475 PMCID: PMC7611932 DOI: 10.1016/s2213-8587(20)30153-4] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 04/14/2020] [Accepted: 04/19/2020] [Indexed: 12/28/2022]
Abstract
BACKGROUND Disordered thyroid hormone transport, due to mutations in the SLC16A2 gene encoding monocarboxylate transporter 8 (MCT8), is characterised by intellectual and motor disability resulting from cerebral hypothyroidism and chronic peripheral thyrotoxicosis. We sought to systematically assess the phenotypic characteristics and natural history of patients with MCT8 deficiency. METHODS We did an international, multicentre, cohort study, analysing retrospective data from Jan 1, 2003, to Dec 31, 2019, from patients with MCT8 deficiency followed up in 47 hospitals in 22 countries globally. The key inclusion criterion was genetically confirmed MCT8 deficiency. There were no exclusion criteria. Our primary objective was to analyse the overall survival of patients with MCT8 deficiency and document causes of death. We also compared survival between patients who did or did not attain full head control by age 1·5 years and between patients who were or were not underweight by age 1-3 years (defined as a bodyweight-for-age Z score <-2 SDs or <5th percentile according to WHO definition). Other objectives were to assess neurocognitive function and outcomes, and clinical parameters including anthropometric characteristics, biochemical markers, and neuroimaging findings. FINDINGS Between Oct 14, 2014, and Jan 17, 2020, we enrolled 151 patients with 73 different MCT8 (SLC16A2) mutations. Median age at diagnosis was 24·0 months (IQR 12·0-60·0, range 0·0-744·0). 32 (21%) of 151 patients died; the main causes of mortality in these patients were pulmonary infection (six [19%]) and sudden death (six [19%]). Median overall survival was 35·0 years (95% CI 8·3-61·7). Individuals who did not attain head control by age 1·5 years had an increased risk of death compared with patients who did attain head control (hazard ratio [HR] 3·46, 95% CI 1·76-8·34; log-rank test p=0·0041). Patients who were underweight during age 1-3 years had an increased risk for death compared with patients who were of normal bodyweight at this age (HR 4·71, 95% CI 1·26-17·58, p=0·021). The few motor and cognitive abilities of patients did not improve with age, as evidenced by the absence of significant correlations between biological age and scores on the Gross Motor Function Measure-88 and Bayley Scales of Infant Development III. Tri-iodothyronine concentrations were above the age-specific upper limit in 96 (95%) of 101 patients and free thyroxine concentrations were below the age-specific lower limit in 94 (89%) of 106 patients. 59 (71%) of 83 patients were underweight. 25 (53%) of 47 patients had elevated systolic blood pressure above the 90th percentile, 34 (76%) of 45 patients had premature atrial contractions, and 20 (31%) of 64 had resting tachycardia. The most consistent MRI finding was a global delay in myelination, which occurred in 13 (100%) of 13 patients. INTERPRETATION Our description of characteristics of MCT8 deficiency in a large patient cohort reveals poor survival with a high prevalence of treatable underlying risk factors, and provides knowledge that might inform clinical management and future evaluation of therapies. FUNDING Netherlands Organisation for Health Research and Development, and the Sherman Foundation.
Collapse
Affiliation(s)
- Stefan Groeneweg
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
| | - Ferdy S van Geest
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
| | - Ayhan Abacı
- Division of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey
| | - Alberto Alcantud
- Pediatric Neurology Section, Hospital Francesc de Borja de Gandia, Valencia, Spain
| | - Gautem P Ambegaonkar
- Department of Paediatric Neurology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Christine M Armour
- Regional Genetics Program, Children's Hospital of Eastern Ontario, and Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
| | | | - Diana Barca
- Paediatric Neurology Clinic, Alexandru Obregia Hospital, Bucharest, Romania; Department of Neurosciences, Paediatric Neurology Discipline II, Carol Davila University of Medicine, Bucharest, Romania
| | - Enrico S Bertini
- Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesu' Children's Research Hospital IRCCS, Rome, Italy
| | - Ingrid M van Beynum
- Sophia Children's Hospital, Division of Paediatric Cardiology, Erasmus Medical Centre, Rotterdam, Netherlands
| | - Nicola Brunetti-Pierri
- Department of Translational Medicine, Federico II University, Naples, Italy; Telethon Institute of Genetics and Medicine, Pozzuoli, Naples, Italy
| | - Marianna Bugiani
- Department of Child Neurology, Center for Childhood White Matter Diseases, Emma Children's Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, and Amsterdam Neuroscience, Amsterdam, Netherlands; Department of Pathology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Marco Cappa
- Division of Endocrinology, Bambino Gesu' Children's Research Hospital IRCCS, Rome, Italy
| | - Gerarda Cappuccio
- Department of Translational Medicine, Federico II University, Naples, Italy; Telethon Institute of Genetics and Medicine, Pozzuoli, Naples, Italy
| | - Barbara Castellotti
- Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | | | - Krishna Chatterjee
- Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Irenaeus F M de Coo
- Department of Paediatric Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
| | - Régis Coutant
- Department of Pediatric Endocrinology and Diabetology, University Hospital, Angers, France
| | - Dana Craiu
- Paediatric Neurology Clinic, Alexandru Obregia Hospital, Bucharest, Romania; Department of Neurosciences, Paediatric Neurology Discipline II, Carol Davila University of Medicine, Bucharest, Romania
| | - Patricia Crock
- John Hunter Children's Hospital and University of Newcastle, Newcastle, NSW, Australia
| | | | - Korcan Demir
- Division of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey
| | - Alice Dica
- Paediatric Neurology Clinic, Alexandru Obregia Hospital, Bucharest, Romania; Department of Neurosciences, Paediatric Neurology Discipline II, Carol Davila University of Medicine, Bucharest, Romania
| | - Paul Dimitri
- Sheffield Children's NHS Foundation Trust, Sheffield Hallam University and University of Sheffield, Sheffield, UK
| | - Anna Dolcetta-Capuzzo
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; Università Vita-Salute San Raffaele, Milan, Italy
| | | | | | - Anina Enderli
- Department of Neuropediatrics, University Children's Hospital Zurich, Zürich, Switzerland
| | - Jan Fairchild
- Department of Diabetes and Endocrinology, Women's and Children's Hospital, North Adelaide, SA, Australia
| | | | - Belinda George
- Department of Endocrinology, St. John's Medical College Hospital, Bengaluru, Karnataka, India
| | - Evelien F Gevers
- Centre for Endocrinology, William Harvey Research institute, Queen Mary University London, London, UK; Dept of Paediatric Endocrinology, Barts Health NHS Trust, London, UK
| | - Annette Hackenberg
- Department of Neuropediatrics, University Children's Hospital Zurich, Zürich, Switzerland
| | - Zita Halász
- Department of Paediatrics, Semmelweis University, Budapest, Hungary
| | - Bianka Heinrich
- Department of Neuropediatrics, University Children's Hospital Zurich, Zürich, Switzerland
| | - Tony Huynh
- Department of Endocrinology & Diabetes, Queensland Children's Hospital, South Brisbane, QLD, Australia; Department of Chemical Pathology, Mater Pathology, South Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Anna Kłosowska
- Medical University of Gdańsk, Department of Paediatrics, Haematology & Oncology, Department of General Nursery, Gdańsk, Poland
| | - Marjo S van der Knaap
- Department of Child Neurology, Center for Childhood White Matter Diseases, Emma Children's Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, and Amsterdam Neuroscience, Amsterdam, Netherlands
| | | | - Daniel Konrad
- Division of Pediatric Endocrinology and Diabetology and Children's Research Center, University Children's Hospital, Zurich, Switzerland
| | - David A Koolen
- Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center (Radboudumc), Nijmegen, Netherlands
| | - Heiko Krude
- Department of Paediatric Endocrinology and Diabetology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Amy Lawson-Yuen
- Genomics Institute Mary Bridge Children's Hospital, MultiCare Health System Tacoma, WA, USA
| | - Jan Lebl
- Department of Paediatrics, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
| | - Michaela Linder-Lucht
- Division of Neuropediatrics and Muscular Disorders, Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg, Germany
| | - Cláudia F Lorea
- Teaching Hospital of Universidade Federal de Pelotas, Pelotas, Brazil
| | - Charles M Lourenço
- Faculdade de Medicina, Centro Universitario Estácio de Ribeirão Preto, Ribeirão Preto, Brazil
| | - Roelineke J Lunsing
- Department of Child Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Greta Lyons
- Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Jana Malikova
- Department of Paediatrics, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
| | - Edna E Mancilla
- Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, PA, USA
| | - Anne McGowan
- Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | - Veronica Mericq
- Institute of Maternal and Child Research, University of Chile, Santiago, Chile; Department of Pediatrics, Clinica Las Condes, Santiago, Chile
| | - Felipe M Lora
- Pediatric Endocrinology Group, Santa Catarina Hospital, São Paulo, Brazil
| | - Carla Moran
- Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK
| | | | - Isabelle Oliver-Petit
- Department of Paediatric Endocrinology and Genetics, Children's Hospital, Toulouse University Hospital, Toulouse, France
| | - Laura Paone
- Division of Endocrinology, Bambino Gesu' Children's Research Hospital IRCCS, Rome, Italy
| | - Praveen G Paul
- Department of Paediatrics, Christian Medical College, Vellore, India
| | - Michel Polak
- Paediatric Endocrinology, Diabetology and Gynaecology Department, Necker Children's University Hospital, Imagine Institute, Paris, France
| | - Francesco Porta
- Department of Paediatrics, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
| | - Fabiano O Poswar
- Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
| | - Christina Reinauer
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Duesseldorf, Germany
| | - Klara Rozenkova
- Department of Paediatrics, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
| | - Tuba S Menevse
- Marmara University School of Medicine Department of Pediatric Endocrinology, Istanbul, Turkey
| | - Peter Simm
- Royal Children's Hospital, Parkville, Melbourne, VIC, Australia
| | - Anna Simon
- Department of Paediatrics, Christian Medical College, Vellore, India
| | - Yogen Singh
- Department of Paediatric Cardiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Marco Spada
- Department of Paediatrics, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
| | - Jet van der Spek
- Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center (Radboudumc), Nijmegen, Netherlands
| | - Milou A M Stals
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
| | - Athanasia Stoupa
- Paediatric Endocrinology, Diabetology and Gynaecology Department, Necker Children's University Hospital, Imagine Institute, Paris, France
| | | | - Davide Tonduti
- Child Neurology Unit, Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy
| | - Serap Turan
- Marmara University School of Medicine Department of Pediatric Endocrinology, Istanbul, Turkey
| | - Corstiaan A den Uil
- Department of Cardiology and Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, Netherlands
| | - Joel Vanderniet
- John Hunter Children's Hospital and University of Newcastle, Newcastle, NSW, Australia
| | | | | | - Jolante Wierzba
- Medical University of Gdańsk, Department of Paediatrics, Haematology & Oncology, Department of General Nursery, Gdańsk, Poland
| | | | - Nicole I Wolf
- Department of Child Neurology, Center for Childhood White Matter Diseases, Emma Children's Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, and Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Michael Wurm
- Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany; KUNO Children's University Hospital, Campus St. Hedwig, University of Regensburg, Regensburg, Germany
| | - Federica Zibordi
- Child Neurology Unit, Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy
| | - Amnon Zung
- Paediatric Endocrinology Unit, Kaplan Medical Center, Rehovot, Israel; Hebrew University of Jerusalem, Jerusalem, Israel
| | - Nitash Zwaveling-Soonawala
- Emma Children's Hospital, Department of Paediatric Endocrinology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - W Edward Visser
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
| |
Collapse
|
6
|
Proust-Lemoine E, Wémeau JL. [Special cases of hyperthyroidism]. Rev Prat 2020; 70:e56-e57. [PMID: 32877151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
|
7
|
Proust-Lemoine E, Wémeau JL. [Hyperthyroidism]. Rev Prat 2020; 70:e47-e55. [PMID: 32877150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
|
8
|
Wémeau JL, Ladsous M. [Goiter, thyroid nodules and thyroid cancers]. Rev Prat 2019; 69:e229-e238. [PMID: 32233333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
| | - Miriam Ladsous
- Praticien hospitalier, centre hospitalier de Valenciennes et CHU de Lille, France
| |
Collapse
|
9
|
Jannin A, Peltier L, d’Herbomez M, Defrance F, Marcelli S, Ben Hamou A, Humbert L, Wémeau JL, Vantyghem MC, Espiard S. Lesson from inappropriate TSH-receptor antibody measurement in hypothyroidism: case series and literature review. ACTA ACUST UNITED AC 2019; 57:e218-e221. [DOI: 10.1515/cclm-2019-0090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2019] [Accepted: 02/06/2019] [Indexed: 11/15/2022]
|
10
|
Ladsous M, Wémeau JL. [Subclinical hypothyroidism]. Rev Prat 2018; 68:e210. [PMID: 30869440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Miriam Ladsous
- Praticien hospitalier, services d'endocrinologie, centre hospitalier de Valenciennes, 59300 Valenciennes, et hôpital Claude-Huriez, CHRU de Lille, 59037 Lille Cedex, France
| | - Jean-Louis Wémeau
- Professeur émérite d'endocrinologie, université de Lille-2, 765, domaine de la Vigne, 59910 Bondues, France
| |
Collapse
|
11
|
Ladsous M, Wémeau JL. [Hypothyroidism]. Rev Prat 2018; 68:e211-e218. [PMID: 30869441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Miriam Ladsous
- Praticien hospitalier, services d'endocrinologie, centre hospitalier de Valenciennes, 59300 Valenciennes, et hôpital Claude-Huriez, CHRU de Lille, 59037 Lille Cedex, France
| | - Jean-Louis Wémeau
- Professeur émérite d'endocrinologie, université de Lille-2, 765, domaine de la Vigne, 59910 Bondues, France
| |
Collapse
|
12
|
Bertagna X, Bouchard P, Grimaldi A, Wémeau JL, Young J. [Levothyrox : time of reason]. Rev Prat 2018; 68:123-125. [PMID: 30801135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Xavier Bertagna
- Professeurs d'endocrinologie (hôpital Cochin [Paris], hôpital Foch [Suresnes], groupe hospitalier La Pitié-Salpêtrière [Paris], hôpital Claude-Huriez [Lille], CHRU Bicêtre [Le Kremlin-Bicêtre])
| | - Philippe Bouchard
- Professeurs d'endocrinologie (hôpital Cochin [Paris], hôpital Foch [Suresnes], groupe hospitalier La Pitié-Salpêtrière [Paris], hôpital Claude-Huriez [Lille], CHRU Bicêtre [Le Kremlin-Bicêtre])
| | - André Grimaldi
- Professeurs d'endocrinologie (hôpital Cochin [Paris], hôpital Foch [Suresnes], groupe hospitalier La Pitié-Salpêtrière [Paris], hôpital Claude-Huriez [Lille], CHRU Bicêtre [Le Kremlin-Bicêtre])
| | - Jean-Louis Wémeau
- Professeurs d'endocrinologie (hôpital Cochin [Paris], hôpital Foch [Suresnes], groupe hospitalier La Pitié-Salpêtrière [Paris], hôpital Claude-Huriez [Lille], CHRU Bicêtre [Le Kremlin-Bicêtre])
| | - Jacques Young
- Professeurs d'endocrinologie (hôpital Cochin [Paris], hôpital Foch [Suresnes], groupe hospitalier La Pitié-Salpêtrière [Paris], hôpital Claude-Huriez [Lille], CHRU Bicêtre [Le Kremlin-Bicêtre])
| |
Collapse
|
13
|
Wémeau JL, Ladsous M. Erratum à l’article : « Lévothyrox® : les enseignements d’une polémique insensée » [Press. Med. 46(10) (2017) 887–9]. Presse Med 2017; 46:1240. [PMID: 29224705 DOI: 10.1016/j.lpm.2017.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- Jean-Louis Wémeau
- CHRU, université de Lille 2, service d'endocrinologie, 59037 Lille cedex, France.
| | - Miriam Ladsous
- CHRU, clinique endocrinologique Marc-Linquette, 59037 Lille cedex, France
| |
Collapse
|
14
|
Wémeau JL, Lorette G. [The mouth talks about endocrinopathies]. Presse Med 2017; 46:820-821. [PMID: 28943222 DOI: 10.1016/j.lpm.2017.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
| | - Gérard Lorette
- CHU Trousseau, université de Tours, service de dermatologie, boulevard Tonnelé, 37044 Tours cedex 09, France.
| |
Collapse
|
15
|
Wémeau JL, Cardot-Bauters C. [Maxillary, buccal and dental expressions of hyperparathyroidisms]. Presse Med 2017; 46:845-852. [PMID: 28579010 DOI: 10.1016/j.lpm.2017.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Revised: 04/11/2017] [Accepted: 05/02/2017] [Indexed: 12/24/2022] Open
Abstract
States of chronic parathyroid hypersecretion, related to a primitive parathyroid abnormality (adenoma, hyperplasia), or to a cause of chronic calcipenia (renal failure, vitamin D deficiency…) have a major impact on bone remodeling, alveolodental structures. Thinning of the lamina dura, maxillary or mandibular brown tumors, giant cell epulis are the most emblematic signs of the primary hyperparathyroidism. Other expressions are related to genetic factors such as fibrous tumors of the jaw in conjunction with mutations in the gene coding for parafibromin.
Collapse
|
16
|
Abstract
Chronic calcipenia related to hypo- and pseudohypoparathyroidism favors trophic complications, especially expressed on the buccal cavity. Correlated with early onset of the disease and imperfect correction of the metabolic disorders, retardation to appearance and implantation of teeth are observed. The buccal signs often are the most immediately visible expression of the disease. They are painful and disabling. Other acute expressions reflect the neuromuscular hyperexcitability related to tetany. Finally, some etiologies determine specific damage, as in Di George's, HDR syndromes or in Albright's osteodystrophia.
Collapse
Affiliation(s)
- François Wémeau
- Centre hospitalier de Calais, 765, domaine de la Vigne, 59910 Bondues, France
| | | |
Collapse
|
17
|
Abstract
Pendred syndrome is an autosomal recessive disorder that is classically defined by the combination of sensorineural deafness/hearing impairment, goiter, and an abnormal organification of iodide with or without hypothyroidism. The hallmark of the syndrome is the impaired hearing, which is associated with inner ear malformations such as an enlarged vestibular aqueduct (EVA). The thyroid phenotype is variable and may be modified by the nutritional iodine intake. Pendred syndrome is caused by biallelic mutations in the SLC26A4/PDS gene, which encodes the multifunctional anion exchanger pendrin. Pendrin has affinity for chloride, iodide, and bicarbonate, among other anions. In the inner ear, pendrin functions as a chloride/bicarbonate exchanger that is essential for maintaining the composition and the potential of the endolymph. In the thyroid, pendrin is expressed at the apical membrane of thyroid cells facing the follicular lumen. Functional studies have demonstrated that pendrin can mediate iodide efflux in heterologous cells. This, together with the thyroid phenotype observed in humans (goiter, impaired iodine organification) suggests that pendrin could be involved in iodide efflux into the lumen, one of the steps required for thyroid hormone synthesis. Iodide efflux can, however, also occur in the absence of pendrin suggesting that other exchangers or channels are involved. It has been suggested that Anoctamin 1 (ANO1/TMEM16A), a calcium-activated anion channel, which is also expressed at the apical membrane of thyrocytes, could participate in mediating apical efflux. In the kidney, pendrin is involved in bicarbonate secretion and chloride reabsorption. While there is no renal phenotype under basal conditions, severe metabolic alkalosis has been reported in Pendred syndrome patients exposed to an increased alkali load. This review provides an overview on the clinical spectrum of Pendred syndrome, the functional data on pendrin with a focus on its potential role in the thyroid, as well as the controversy surrounding the relative physiological roles of pendrin and anoctamin.
Collapse
Affiliation(s)
- Jean-Louis Wémeau
- Université de Lille 2, Centre Hospitalier Régional Universitaire de Lille, Clinique Endocrinologique Marc-Linquette, 59037 Lille, France.
| | - Peter Kopp
- Northwestern University, Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Tarry 15, 303 East Chicago Avenue, Chicago, IL 60611, USA.
| |
Collapse
|
18
|
Abstract
Pasireotide, the latest long-acting release somatostatin analogue, is distributed more widely to the various somatostatin receptors, which theoretically increases its strength and broadens its scope. Does this reflect genuine therapeutic progress? Or rather does its reduced specificity cause too many adverse reactions to make it a significant therapeutic achievement?
Collapse
Affiliation(s)
- Jean-Louis Wémeau
- Université de Lille 2, CHRU de Lille, Clinique endocrinologique Marc-Linquette, 59037 Lille cedex, France.
| |
Collapse
|
19
|
Espiard S, Petyt G, Lion G, Béron A, Do Cao C, Wémeau JL, Vantyghem MC, Pattou F, Caiazzo R. Ectopic Subcutaneous Implantation of Thyroid Tissue After Gasless Transaxillary Robotic Thyroidectomy for Papillary Thyroid Cancer. Thyroid 2015; 25:1381-2. [PMID: 26563453 DOI: 10.1089/thy.2015.0177] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Stéphanie Espiard
- 1 Department of Endocrinology and Metabolism, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Gregory Petyt
- 2 Department of Nuclear Medicine, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Georges Lion
- 2 Department of Nuclear Medicine, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Amandine Béron
- 2 Department of Nuclear Medicine, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Christine Do Cao
- 1 Department of Endocrinology and Metabolism, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Jean-Louis Wémeau
- 1 Department of Endocrinology and Metabolism, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Marie-Christine Vantyghem
- 1 Department of Endocrinology and Metabolism, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Francois Pattou
- 3 Department of Endocrine Surgery, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| | - Robert Caiazzo
- 3 Department of Endocrine Surgery, Centre Hospitalier Regional Universitaire de Lille , Lille, France
| |
Collapse
|
20
|
Balavoine AS, Glinoer D, Dubucquoi S, Wémeau JL. Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem? Thyroid 2015; 25:1273-81. [PMID: 26414658 DOI: 10.1089/thy.2014.0603] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND The aim of this review was to delineate the characteristics of antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis associated with antithyroid drugs (ATD). A PubMed search was made for English language articles using the search terms antithyroid drugs AND ANCA OR ANCA-associated vasculitis. SUMMARY The literature includes approximately 260 case reports of ANCA-associated small-vessel vasculitis related to ATD, with 75% of these associated with thiouracil derivatives (propylthiouracil [PTU]) and 25% with methyl-mercapto-imidazole derivatives (MMI/TMZ). The prevalence of ANCA-positive cases caused by ATD varied between 4% and 64% with PTU (median 30%), and 0% and 16% with MMI/TMZ (median 6%). Young age and the duration of ATD therapy were the main factors contributing to the emergence of ANCA positivity. Before ATD therapy initiation, the prevalence of ANCA-positive patients was 0-13%. During ATD administration, 20% of patients were found to be positive for ANCA. Only 15% of ANCA-positive patients treated with ATD exhibited clinical evidence of vasculitis, corresponding to 3% of all patients who received ATD. Clinical manifestations of ANCA-associated vasculitis related to ATD were extremely heterogeneous. When vasculitis occurred, ATD withdrawal was usually followed by rapid clinical improvement and a favorable prognosis. CONCLUSIONS ANCA screening is not systematically recommended for individuals on ATD therapy, particularly given the decreasing use of PTU in favor of TMZ/MMI. Particular attention should be given to the pediatric population with Graves' disease who receive ATD, as well as patients treated with thiouracil derivatives and those on long-term ATD therapy.
Collapse
Affiliation(s)
| | - Daniel Glinoer
- 2 Department of Internal Medicine, Division of Endocrinology, University Hospital Saint Pierre , Brussels, Belgium
| | | | - Jean-Louis Wémeau
- 1 Service of Endocrinology and Metabolic Diseases, CHRU de Lille , Lille, France
- 3 Institut d'Immunologie, CHRU de Lille , Lille, France
| |
Collapse
|
21
|
Wémeau JL. The expanding spectrum of thyroid hormone resistance concerns the entire medical field. Presse Med 2015; 44:1093-5. [PMID: 26615083 DOI: 10.1016/j.lpm.2015.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Affiliation(s)
- Jean-Louis Wémeau
- CHRU de Lille, clinique endocrinologique Marc-Linquette, service d'endocrinologie et des maladies métaboliques, 59037 Lille cedex, France.
| |
Collapse
|
22
|
Dubucquoi S, Proust-Lemoine E, Kemp EH, Ryndak A, Lefèvre-Dutoit V, Bellart M, Saugier-Véber P, Duban-Deweer S, Wémeau JL, Prin L, Lefranc D. Serological proteome analysis reveals new specific biases in the IgM and IgG autoantibody repertoires in autoimmune polyendocrine syndrome type 1. Autoimmunity 2015; 48:532-41. [PMID: 26312540 DOI: 10.3109/08916934.2015.1077230] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
OBJECTIVE Autoimmune polyendocrine syndrome type 1 (APS 1) is caused by mutations in the AIRE gene that induce intrathymic T-cell tolerance breakdown, which results in tissue-specific autoimmune diseases. DESIGN To evaluate the effect of a well-defined T-cell repertoire impairment on humoral self-reactive fingerprints, comparative serum self-IgG and self-IgM reactivities were analyzed using both one- and two-dimensional western blotting approaches against a broad spectrum of peripheral tissue antigens. METHODS Autoantibody patterns of APS 1 patients were compared with those of subjects affected by other autoimmune endocrinopathies (OAE) and healthy controls. RESULTS Using a Chi-square test, significant changes in the Ab repertoire were found when intergroup patterns were compared. A singular distortion of both serum self-IgG and self-IgM repertoires was noted in APS 1 patients. The molecular characterization of these antigenic targets was conducted using a proteomic approach. In this context, autoantibodies recognized more significantly either tissue-specific antigens, such as pancreatic amylase, pancreatic triacylglycerol lipase and pancreatic regenerating protein 1α, or widely distributed antigens, such as peroxiredoxin-2, heat shock cognate 71-kDa protein and aldose reductase. As expected, a well-defined self-reactive T-cell repertoire impairment, as described in APS 1 patients, affected the tissue-specific self-IgG repertoire. Interestingly, discriminant IgM reactivities targeting both tissue-specific and more widely expressed antigens were also specifically observed in APS 1 patients. Using recombinant targets, we observed that post translational modifications of these specific antigens impacted upon their recognition. CONCLUSIONS The data suggest that T-cell-dependent but also T-cell-independent mechanisms are involved in the dynamic evolution of autoimmunity in APS 1.
Collapse
Affiliation(s)
- Sylvain Dubucquoi
- a CHRU Lille, Institut d'Immunologie - Centre de Biologie Pathologie et Génétique , Lille , France
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
| | - Emmanuelle Proust-Lemoine
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
- d CHRU Lille Service d'Endocrinologie , Lille , France
| | - E Helen Kemp
- e Department of Human Metabolism , University of Sheffield , Sheffield , UK
| | - Amélie Ryndak
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
- d CHRU Lille Service d'Endocrinologie , Lille , France
| | - Virginie Lefèvre-Dutoit
- a CHRU Lille, Institut d'Immunologie - Centre de Biologie Pathologie et Génétique , Lille , France
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
| | - Marine Bellart
- a CHRU Lille, Institut d'Immunologie - Centre de Biologie Pathologie et Génétique , Lille , France
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
| | | | - Sophie Duban-Deweer
- c Univ Lille Nord de France , Lille , France
- g UArtois, LBHE , EA 2465 , Lens , France
| | - Jean-Louis Wémeau
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
- d CHRU Lille Service d'Endocrinologie , Lille , France
| | - Lionel Prin
- a CHRU Lille, Institut d'Immunologie - Centre de Biologie Pathologie et Génétique , Lille , France
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
| | - Didier Lefranc
- b UDSL, EA 2686, UFR Médecine , Lille , France
- c Univ Lille Nord de France , Lille , France
| |
Collapse
|
23
|
Espiard S, Savagner F, Flamant F, Vlaeminck-Guillem V, Guyot R, Munier M, d'Herbomez M, Bourguet W, Pinto G, Rose C, Rodien P, Wémeau JL. A Novel Mutation in THRA Gene Associated With an Atypical Phenotype of Resistance to Thyroid Hormone. J Clin Endocrinol Metab 2015; 100:2841-8. [PMID: 26037512 DOI: 10.1210/jc.2015-1120] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
CONTEXT RTHα is a recently discovered resistance to thyroid hormone (RTH) due to mutation of THRA, the gene encoding TRα1, the thyroid hormone receptor. It has been described in a few patients with growth retardation, short stature, and a low free T4/free T3 (FT4/FT3) ratio. OBJECTIVE A 27-year-old patient presenting with dwarfism and a low FT4/FT3 ratio was investigated. DESIGN Clinical, biochemical, and radiological data were collected. Whole exome sequencing was performed in the patient and her relatives. RESULTS The patient exhibited congenital macrocytic anemia and severe bone malformation with growth retardation, dwarfism, clavicular agenesis, and abnormalities of the fingers, toes, and elbow joints. In adulthood, she presented with active behavior, chronic motor diarrhea, and hypercalcemia. Treatment with T3 led to heart rate acceleration, worsening of diarrhea, and TSH suppression. Low resting energy expenditure normalized on T3. rT3, SHBG, and IGF-1 remained normal. A de novo monoallelic missense mutation in THRA was discovered, the N359Y amino acid substitution (c.1075A>T), which affected both the TRα1 and the non-receptor isoform TRα2. The mutant TRα1 had a decrease in transcriptional activity related to decreased T3 binding and a dominant-negative effect on the wild-type receptor. CONCLUSIONS This patient presents a new phenotype including more significant bone abnormalities, lower TSH, and higher FT3 levels, without certainty of all her symptoms with the TRα1(N359Y) mutation. This case suggests that patients with a low FT4/FT3 ratio should be screened for THRA mutations, even if clinical and biological features differ from previous reported cases of RTHα.
Collapse
Affiliation(s)
- Stéphanie Espiard
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Frédérique Savagner
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Frédéric Flamant
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Virginie Vlaeminck-Guillem
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Romain Guyot
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Mathilde Munier
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Michele d'Herbomez
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - William Bourguet
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Graziella Pinto
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Christian Rose
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Patrice Rodien
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Jean-Louis Wémeau
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| |
Collapse
|
24
|
Wémeau JL. The parathyroid glands: An object of universal fascination. Ann Endocrinol (Paris) 2015; 76:77-79. [PMID: 25911001 DOI: 10.1016/j.ando.2015.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- Jean-Louis Wémeau
- Service d'endocrinologie et des maladies métaboliques, clinique endocrinologique Marc-Linquette, hôpital Claude-Huriez, CHRU, 59037 Lille cedex, France.
| |
Collapse
|
25
|
Wémeau JL. Monitoring of hypo- and pseudohypoparathyroidism. Ann Endocrinol (Paris) 2015; 76:185-186. [PMID: 25916758 DOI: 10.1016/j.ando.2015.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Accepted: 03/20/2015] [Indexed: 06/04/2023]
Affiliation(s)
- Jean-Louis Wémeau
- Service d'endocrinologie et des maladies métaboliques, clinique endocrinologique Marc-Linquette, CHRU de Lille, 59037 Lille cedex, France.
| |
Collapse
|
26
|
Vélayoudom-Céphise FL, Wémeau JL. Primary hyperparathyroidism and vitamin D deficiency. Ann Endocrinol (Paris) 2015; 76:153-62. [PMID: 25916759 DOI: 10.1016/j.ando.2015.03.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 03/11/2015] [Indexed: 12/01/2022]
Abstract
Primary hyperparathyroidism (PHPT) and vitamin D (VD) deficiency are frequent conditions due to the widespread application of assays for calcium and VD. PHPT presentation is dominated by diversity in its expression and the current predominance of asymptomatic forms. VD, which plays a major role in calcium and phosphate homeostasis, is also involved in many physiological processes in this disease, such as lipid and glucose metabolism, and in the signalling pathways and functioning of many cell types. The bone and cardiometabolic complications described in PHPT are exacerbated by vitamin D deficiency, the prevalence of which varies according to many parameters (environment, skin pigmentation, associated chronic diseases, liver and kidney function, assay kit used, etc.). In response to this observation, experts in field from medical societies validated the indication for systematic assay of VD occurring with PHPT and the need for replacement in case of deficiency. Several epidemiological studies have confirmed that replacement with natural vitamin D is well tolerated and safe in subjects with PHPT and VD deficiency. This supplementation reduces hyperparathormonemia, does not have symptomatic effects on calciuria, and especially improves the bone and functional condition of patients.
Collapse
Affiliation(s)
- Fritz-Line Vélayoudom-Céphise
- Service d'endocrinologie-diabétologie, CHU de Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe; Équipe de recherche ECM-LAMIA EA4540, université des Antilles, Antilles, Guadeloupe.
| | - Jean-Louis Wémeau
- Clinique endocrinologique Marc-Linquette, CHRU de Lille, 59037 Lille, France
| |
Collapse
|
27
|
Renaud F, Gnemmi V, Devos P, Aubert S, Crépin M, Coppin L, Ramdane N, Bouchindhomme B, d'Herbomez M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wémeau JL, Leteurtre E. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Thyroid 2014; 24:1375-84. [PMID: 25012490 DOI: 10.1089/thy.2013.0594] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND The incidence of papillary thyroid carcinoma (PTC) has increased over the past 30 years in Western countries. PTC is usually associated with a good prognosis, but there is a wide range of aggressiveness, and some patients develop distant metastasis and/or resistance to standard treatment. Early identification of these high-risk tumors is a current challenge for appropriate patient management. MUC1 expression has been studied previously in thyroid cancer, but its prognostic value remains controversial. Here, we correlated MUC1 expression in PTC with clinical and pathological features and with the presence of the BRAF(V600E) mutation. METHODS We performed a clinical and morphological analysis of 190 thyroid tumors (95 PTCs and 95 adenomas). MUC1 immunohistochemistry was carried out on a tissue microarray using different antibodies. The presence of the BRAF(V600E) mutation was investigated by pyrosequencing. MUC1 mRNA levels were assessed by quantitative reverse transcription polymerase chain reaction on a subset of PTC. RESULTS MUC1 expression was observed in 49% of PTCs and was found to correlate with the presence of papillary architecture, a stromal lymphoid infiltrate, aggressive histological subtypes, extrathyroidal extension, lymph node metastasis, nuclear pseudoinclusions, lymphovascular invasion, and the presence of the BRAF(V600E) mutation (p<0.0001). MUC1 was abundant in nuclear pseudoinclusions. Multivariate analysis showed a strong association of MUC1 expression with the presence of the BRAF(V600E) mutation and lymph node metastasis (p<0.0001). Lymph node metastasis was the most important risk factor of relapse. CONCLUSIONS Our study shows an association between MUC1 expression and the presence of the BRAF(V600E) mutation in PTC. Analysis of MUC1 expression could improve the risk stratification of PTCs.
Collapse
Affiliation(s)
- Florence Renaud
- 1 Institute of Pathology, Lille University Hospital , Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Wémeau JL. [Autoimmune polyendocrine syndromes type 2]. Rev Prat 2014; 64:838-839. [PMID: 25090774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
29
|
Cardot-Bauters C, Wémeau JL. [Autoimmune thyroiditis]. Rev Prat 2014; 64:835-838. [PMID: 25090773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Autoimmune thyroiditis are common and benign disorders, affecting preferentially women, at any age of life. They may occur singly or integrated as a part of familial predisposition to autoimmune thyroid disease or autoimmune polyendocrinopathies. Clinical presentation is variable: goiter or thyroid atrophy, euthyroid or temporary or permanent hypothyroidism, rarely transient thyrotoxicosis. Commune features are the presence of antithyroperoxydase antibodies and lymphoplasmocytic infiltrate of the thyroid parenchyma. It is important to distinguish the cases in which thyroid dysfunction is transient and requires only monitoring and those in which hypothyroidism is permanent and justifies thyroid hormone replacement. In the forms with goiter, clinical and ultrasonic control of the thyroid is justified.
Collapse
|
30
|
Bertagna X, Wémeau JL. La surrénale en 2014. Presse Med 2014; 43:364-5. [DOI: 10.1016/j.lpm.2014.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
31
|
Ladsous M, Vlaeminck-Guillem V, Dumur V, Vincent C, Dubrulle F, Dhaenens CM, Wémeau JL. Analysis of the thyroid phenotype in 42 patients with Pendred syndrome and nonsyndromic enlargement of the vestibular aqueduct. Thyroid 2014; 24:639-48. [PMID: 24224479 DOI: 10.1089/thy.2013.0164] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Pendred syndrome (PS), a recessive disorder caused by mutations in the SLC26A4 (PDS) gene, is associated with deafness and goiter. SLC26A4 mutations have also been identified in patients exhibiting isolated sensorineural hearing loss without apparent thyroid abnormality (nonsyndromic enlargement of the vestibular aqueduct; nonsyndromic EVA). Our aim was to describe systematically the thyroidal phenotypes and the SLC26A4 genotypes of patients presenting with PS or nonsyndromic EVA. METHODS Nineteen patients with PS and 23 patients with nonsyndromic EVA, aged 5-53 years, were included. They underwent thyroid evaluation (physical examination, biological thyroid function tests, measurement of thyroglobulin level, thyroid ultrasonography, and thyroid (123)I scintigraphy with perchlorate discharge test), otological evaluation, and SLC26A4 mutation screening. RESULTS In 19 patients with PS, goiter was identified in 15 (79%) and hypothyroidism in 15 (79%); hypothyroidism was subclinical in four patients and congenital in six patients. The perchlorate discharge test (PDT) was positive in 10/16 (63%). Morphological evaluation of the inner ear using MRI and/or CT showed bilateral EVA in 15/15 PS patients. Mutation screening revealed two SLC26A4 mutant alleles in all 19 PS patients that were homozygous in two families and compound heterozygous in 12 families. In the 23 patients with nonsyndromic EVA, systematic thyroid evaluation found no abnormalities except for slightly increased thyroglobulin levels in two patients. SLC26A4 mutations were identified in 9/23 (39%). Mutations were biallelic in two (compound heterozygous) and monoallelic in seven patients. CONCLUSION The thyroid phenotype is widely variable in PS. SLC26A4 mutation screening is needed in patients exhibiting PS or nonsyndromic EVA. PS is associated with biallelic SLC26A4 mutations and nonsyndromic EVA with no, monoallelic, or biallelic SLC26A4 mutations. Systematic thyroid evaluation is recommended in patients with nonsyndromic EVA associated with one or two SLC26A4 mutations. We propose using a combination of three parameters to define and diagnose PS: (i) sensorineural deafness with bilateral EVA; (ii) thyroid abnormality comprising goiter and/or hypothyroidism and/or a positive PDT; (iii) biallelic SLC26A4 mutations.
Collapse
Affiliation(s)
- Miriam Ladsous
- 1 Department of Endocrinology, Regional University Hospital Center (CHRU) of Lille, Lille, France
| | | | | | | | | | | | | |
Collapse
|
32
|
Orgiazzi J, Wémeau JL. [Levothyroxine and generics: current reflections]. Rev Prat 2014; 64:304-306. [PMID: 24851355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
33
|
|
34
|
Abstract
TSH assay is the best parameter of the thyroid function. For adults, the normal interval of TSH concentrations range from 0.4 to 4 mUI/L. At the first trimester of pregnancy, TSH levels must be <2.5 mUI/L. Normal TSH levels increase with aging and obesity. The biological diagnosis relies on the identification of excessive secretion of the metanephrines which are more sensitive and specific than those of catecholamines. The concentrations of the free plasmatic metanephrines reflect the ongoing production of tumor. Plasma methoxytyramine is a novel biomarker of metastatic pheochromocytomas and paragangliomas. Serum IGF1 is a reliable measure of integrated GH concentrations in patients with acromegaly. Accurate assessment of IGF1 concentrations requires age and sex-matched control values. IGF1 is a sensitive tool for the diagnosis of acromegaly and efficacy of therapies. Serum AMH assay is more sensitive, more specific and more reproducible that counting of ovarian follicles by ultrasound. AMH level above 5 ng/mL (35 pmol/L) could be chosen as one of the diagnostic criteria for the polycystic ovary syndrome. In early or "incipiens" ovarian failure, the decrease in serum AMH is far ahead of the increase in FSH. Thyroglobulin (TG) and calcitonin (CT) are the sensitive and specific markers of respectively well-differentiated thyroid cancers of follicular origin and of the medullary thyroid cancers. The same tumour marker assay should be used to monitor a given patient. Chromogranin A (CgA) is a highly efficient biomarker for diagnosis and follow-up of various endocrine tumours. Despite the lack of international standardisation, some CgA assays are reliable.
Collapse
Affiliation(s)
- Michèle d'Herbomez
- Université de Lille II, 59800 Lille, France; CHRU de Lille, centre de biologie-pathologie-génétique, rue Émile-Laine, 59037 Lille cedex, France.
| | - Catherine Bauters
- Clinique d'endocrinologie Marc-Linquette, hôpital Huriez, 59037 Lille cedex, France
| | | | - Didier Dewailly
- Université de Lille II, 59800 Lille, France; Hôpital Jeanne-de-Flandre, service de gynécologie endocrinienne et médecine de la reproduction, 59037 Lille cedex, France
| | - Christine Docao
- Clinique d'endocrinologie Marc-Linquette, hôpital Huriez, 59037 Lille cedex, France
| | - Jean-Louis Wémeau
- Université de Lille II, 59800 Lille, France; Clinique d'endocrinologie Marc-Linquette, hôpital Huriez, 59037 Lille cedex, France
| |
Collapse
|
35
|
Leroy C, Karrouz W, Douillard C, Do Cao C, Cortet C, Wémeau JL, Vantyghem MC. Diabetes insipidus. Annales d'Endocrinologie 2013; 74:496-507. [DOI: 10.1016/j.ando.2013.10.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2013] [Revised: 09/23/2013] [Accepted: 10/07/2013] [Indexed: 01/13/2023]
|
36
|
Wémeau JL, Bouchard P. [Endocrine gynecology: an attractive discipline]. Presse Med 2013; 42:1486. [PMID: 24267722 DOI: 10.1016/j.lpm.2013.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Jean-Louis Wémeau
- CHRU de Lille, clinique endocrinologique Marc-Linquette, hôpital Claude-Huriez, 4(e) et 5(e) Ouest, 59037 Lille cedex, France.
| | | |
Collapse
|
37
|
Wémeau JL, Ryndak A, Karrouz W, Balavoine AS, Baudoux F. [Hand and endocrine diseases]. Presse Med 2013; 42:1596-606. [PMID: 24148694 DOI: 10.1016/j.lpm.2013.03.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 03/11/2013] [Accepted: 03/14/2013] [Indexed: 11/28/2022] Open
Abstract
The whole of hormones likely influence state of hands, modifying colouring and trophicity of the skin and having influence on its muscular, tendineous, osseous, articular components. Thus state of the hands contributes to the recognition of the endocrine diseases: hot and moist hands of the Graves' disease, dry, cold and infiltrated hands in myxoedema, pale and fine hands of hypopituitarism, broad and thick hand of acromegaly, brachymetacarpia in the pseudohypoparathyroidism… Diabetes exposes particularly to tendineous and articular retractions, to whitlows and ungual mycosis.
Collapse
Affiliation(s)
- Jean-Louis Wémeau
- Clinique endocrinologique Marc-Linquette, hôpital Claude-Huriez, CHRU de Lille, 4(e) et 5(e) Ouest, 59037 Lille cedex, France.
| | | | | | | | | |
Collapse
|
38
|
|
39
|
Karrouz W, Kamoun M, Odou MF, Pigny P, Caiazzo R, Pattou F, Leteurtre E, Wémeau JL, Vantyghem MC. Hibernoma and type 1 multiple endocrine neoplasia (MEN1)? A metabolic link? Annales d'Endocrinologie 2013. [DOI: 10.1016/j.ando.2013.03.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Espiard S, Balavoine AS, Mouton F, Fry S, Vantyghem MC, Wémeau JL. Troubles endocriniens chez une patiente polymédicamentée. Presse Med 2013; 42:378-81. [DOI: 10.1016/j.lpm.2012.01.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Revised: 01/21/2012] [Accepted: 01/27/2012] [Indexed: 11/26/2022] Open
|
41
|
Abstract
Even though autoimmune thyroiditis is considered as the most emblematic type of organ-specific autoimmune disorder of autoimmunity, autoimmune thyroid diseases can be associated with other autoimmune endocrine failures or non-endocrine diseases (namely vitiligo, pernicious anemia, myasthenia gravis, autoimmune gastritis, celiac disease, hepatitis). Thyroid disorders, which are the most frequent expression of adult polyendocrine syndrome type 2, occur concomitantly with or secondarily to insulinodependent diabetes, premature ovarian failure, Addison's disease (Schmidt syndrome, or Carpenter syndrome if associated with diabetes). Testicular failure and hypoparathyroidism are unusual. The disease is polygenic and multifactorial. Disorders of thyroid autoimmunity are, surprisingly, very rare in polyendocrine syndrome type 1 (or APECED) beginning during childhood. They are related to mutations of the AIRE gene that encodes for a transcriptional factor implicated in central and peripheral immune tolerance. Hypothyroidism can also be observed in the very rare IPEX and POEMS syndromes.
Collapse
Affiliation(s)
- Jean-Louis Wémeau
- Clinique Endocrinologique Marc Linquette, Service d'Endocrinologie et des Maladies Métaboliques, Hôpital Claude Huriez, 4(ème) Ouest, CHRU, Lille Cedex, France.
| | | | | | | |
Collapse
|
42
|
Affiliation(s)
- Jean-Louis Wémeau
- CHRU, hôpital Claude-Huriez, clinique endocrinologique Marc-Linquette, 59037 Lille cedex, France.
| |
Collapse
|
43
|
Abstract
Polyglandular Autoimmune Syndrom type 1 (PAS-1) or Autoimmune PolyEndocrinopathy Candidiasis-Ectodermal-Dystrophy (APECED) is a rare recessive autosomal disease related to Autoimmune Regulator (AIRE) gene mutations. AIRE is mainly implicated in central and peripheric immune tolerance. Diagnosis was classically based on presence of at least two out of three "majors" criterions of Whitaker's triad (candidiasis, autoimmune hypoparathyroidism and adrenal insufficiency). Presence of one criterion was sufficient when a sibling was previously diagnosed. However, some atypic or poorly symptomatic variants do not correspond to these criterions. As a matter of fact, digestive (malabsorption, pernicious anemia, hepatitis), cutaneous (alopecia, vitiligo, enamel dysplasia) or ophtalmological (keratitis) components could prevail. In these cases, diagnosis could be made by molecular genetics. Prognosis is influenced by genetic (AIRE mutations, HLA), hormonal and environmental (infections) factors. Potentially letal components (hepatitis and severe malabsorption) could be treated by immunosuppressors. Candidiasis and other infections should be carefully screened and treated before beginning those therapies, in order to avoid severe systemic infections.
Collapse
Affiliation(s)
- Emmanuelle Proust-Lemoine
- CHRU de Lille, hôpital Claude-Huriez, clinique endocrinologique Marc-Linquette, 4e Ouest, 59037 Lille cedex, France
| | | | | |
Collapse
|
44
|
Vantyghem MC, Balavoine AS, Douillard C, Defrance F, Dieudonne L, Mouton F, Lemaire C, Bertrand-Escouflaire N, Bourdelle-Hego MF, Devemy F, Evrard A, Gheerbrand D, Girardot C, Gumuche S, Hober C, Topolinski H, Lamblin B, Mycinski B, Ryndak A, Karrouz W, Duvivier E, Merlen E, Cortet C, Weill J, Lacroix D, Wémeau JL. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris) 2012; 73:170-89. [PMID: 22748602 DOI: 10.1016/j.ando.2012.04.010] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 04/25/2012] [Accepted: 04/25/2012] [Indexed: 11/15/2022]
Abstract
The spectrum of adipose tissue diseases ranges from obesity to lipodystrophy, and is accompanied by insulin resistance syndrome, which promotes the occurrence of type 2 diabetes, dyslipidemia and cardiovascular complications. Lipodystrophy refers to a group of rare diseases characterized by the generalized or partial absence of adipose tissue, and occurs with or without hypertrophy of adipose tissue in other sites. They are classified as being familial or acquired, and generalized or partial. The genetically determined partial forms usually occur as Dunnigan syndrome, which is a type of laminopathy that can also manifest as muscle, cardiac, neuropathic or progeroid involvement. Gene mutations encoding for PPAR-gamma, Akt2, CIDEC, perilipin and the ZMPSTE 24 enzyme are much more rare. The genetically determined generalized forms are also very rare and are linked to mutations of seipin AGPAT2, FBN1, which is accompanied by Marfan syndrome, or of BANF1, which is characterized by a progeroid syndrome without insulin resistance and with early bone complications. Glycosylation disorders are sometimes involved. Some genetically determined forms have recently been found to be due to autoinflammatory syndromes linked to a proteasome anomaly (PSMB8). They result in a lipodystrophy syndrome that occurs secondarily with fever, dermatosis and panniculitis. Then there are forms that are considered to be acquired. They may be iatrogenic (protease inhibitors in HIV patients, glucocorticosteroids, insulin, graft-versus-host disease, etc.), related to an immune system disease (sequelae of dermatopolymyositis, autoimmune polyendocrine syndromes, particularly associated with type 1 diabetes, Barraquer-Simons and Lawrence syndromes), which are promoted by anomalies of the complement system. Finally, lipomatosis is currently classified as a painful form (adiposis dolorosa or Dercum's disease) or benign symmetric multiple form, also known as Launois-Bensaude syndrome or Madelung's disease, which are sometimes related to mitochondrial DNA mutations, but are usually promoted by alcohol. In addition to the medical management of metabolic syndrome and the sometimes surgical treatment of lipodystrophy, recombinant leptin provides hope for genetically determined lipodystrophy syndromes, whereas modifications in antiretroviral treatment and tesamorelin, a GHRH analog, is effective in the metabolic syndrome of HIV patients. Other therapeutic options will undoubtedly be developed, dependent on pathophysiological advances, which today tend to classify genetically determined lipodystrophy as being related to laminopathy or to lipid droplet disorders.
Collapse
Affiliation(s)
- Marie-Christine Vantyghem
- Inserm U859, service d'endocrinologie et maladies métaboliques, hôpital Huriez, CHRU de Lille, 1, rue Polonovski, 59000 Lille, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea ML, Naves LA, Rodien P, Rohmer V, Faucz FR, Caron P, Estour B, Lecomte P, Borson-Chazot F, Penfornis A, Yaneva M, Guitelman M, Castermans E, Verhaege C, Wémeau JL, Tabarin A, Fajardo Montañana C, Delemer B, Kerlan V, Sadoul JL, Cortet Rudelli C, Archambeaud F, Zacharieva S, Theodoropoulou M, Brue T, Enjalbert A, Bours V, Pellegata NS, Beckers A. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer 2012; 19:233-41. [PMID: 22291433 DOI: 10.1530/erc-11-0362] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Familial isolated pituitary adenoma (FIPA) occurs in families and is unrelated to multiple endocrine neoplasia type 1 and Carney complex. Mutations in AIP account only for 15-25% of FIPA families. CDKN1B mutations cause MEN4 in which affected patients can suffer from pituitary adenomas. With this study, we wanted to assess whether mutations in CDKN1B occur among a large cohort of AIP mutation-negative FIPA kindreds. Eighty-eight AIP mutation-negative FIPA families were studied and 124 affected subjects underwent sequencing of CDKN1B. Functional analysis of putative CDKN1B mutations was performed using in silico and in vitro approaches. Germline CDKN1B analysis revealed two nucleotide changes: c.286A>C (p.K96Q) and c.356T>C (p.I119T). In vitro, the K96Q change decreased p27 affinity for Grb2 but did not segregate with pituitary adenoma in the FIPA kindred. The I119T substitution occurred in a female patient with acromegaly. p27(I119T) shows an abnormal migration pattern by SDS-PAGE. Three variants (p.S56T, p.T142T, and c.605+36C>T) are likely nonpathogenic because In vitro effects were not seen. In conclusion, two patients had germline sequence changes in CDKN1B, which led to functional alterations in the encoded p27 proteins in vitro. Such rare CDKN1B variants may contribute to the development of pituitary adenomas, but their low incidence and lack of clear segregation with affected patients make CDKN1B sequencing unlikely to be of use in routine genetic investigation of FIPA kindreds. However, further characterization of the role of CDKN1B in pituitary tumorigenesis in these and other cases could help clarify the clinicopathological profile of MEN4.
Collapse
Affiliation(s)
- Maria A Tichomirowa
- Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart-Tilman, University of Liège, 4000 Liège, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Vantyghem MC, Balavoine AS, Wémeau JL, Douillard C. Hyponatremia and antidiuresis syndrome. Ann Endocrinol (Paris) 2011; 72:500-12. [PMID: 22119069 DOI: 10.1016/j.ando.2011.10.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Accepted: 10/07/2011] [Indexed: 12/27/2022]
Abstract
Antidiuretic hormone (ADH), or arginine vasopressin (AVP), is primarily regulated through plasma osmolarity, as well as non-osmotic stimuli including blood volume and stress. Links between water-electrolyte and carbohydrate metabolism have also been recently demonstrated. AVP acts via the intermediary of three types of receptors: V1a, or V1, which exerts vasoconstrictive effects; pituitary gland V1b, or V3, which participates in the secretion of ACTH; and renal V2, which reduces the excretion of pure water by combining with water channels (aquaporin 2). Antidiuresis syndrome is a form of euvolaemic, hypoosmolar hyponatraemia, which is characterised by a negative free water clearance with inappropriate urine osmolality and intracellular hyper-hydration in the absence of renal, adrenal and thyroid insufficiency. Ninety percent of cases of antidiuresis syndrome occur in association with hypersecretion of vasopressin, while vasopressin is undetectable in 10% of cases. Thus the term "antidiuresis syndrome" is more appropriate than the classic name "syndrome of inappropriate ADH secretion" (SIADH). The clinical symptoms, morbidity and mortality of hyponatraemia are related to its severity, as well as to the rapidity of its onset and duration. Even in cases of moderate hyponatraemia that are considered asymptomatic, there is a very high risk of falls due to gait and attention disorders, as well as rhabdomyolysis, which increases the fracture risk. The aetiological diagnosis of hyponatraemia is based on the analysis of calculated or measured plasma osmolality (POsm), as well as blood volume (skin tenting of dehydration, oedema). Hyperglycaemia and hypertriglyceridaemia lead to hyper- and normoosmolar hyponatraemia, respectively. Salt loss of gastrointestinal, renal, cutaneous and sometimes cerebral origin is hypovolaemic, hypoosmolar hyponatraemia (skin tenting), whereas oedema is present with hypervolaemic, hypoosmolar hyponatraemia of heart failure, nephrotic syndrome and cirrhosis. Some endocrinopathies (glucocorticoid deficiency and hypothyroidism) are associated with euvolaemic, hypoosmolar hyponatraemia, which must be distinguished from SIADH. Independent of adrenal insufficiency, isolated hypoaldosteronism can also be accompanied by hypersecretion of vasopressin secondary to hypovolaemia, which responds to mineralocorticoid administration. The causes of SIADH are classic: neoplastic (notably small-cell lung cancer), iatrogenic (particularly psychoactive drugs, chemotherapy), lung and cerebral. Some causes have been recently described: familial hyponatraemia via X-linked recessive disease caused by an activating mutation of the vasopressin 2 receptor; and corticotropin insufficiency related to drug interference between some inhaled glucocorticoids and cytochrome p450 inhibitors, such as the antiretroviral drugs and itraconazole, etc. SIADH in marathon runners exposes them to a risk of hypotonic encephalopathy with fatal cerebral oedema. SIADH treatment is based on water restriction and demeclocycline. V2 receptor antagonists are still not marketed in France. These aquaretics seem effective clinically and biologically, without demonstrated improvement to date of mortality in eu- and hypervolaemic hyponatraemia. Obviously treatment of a corticotropic deficit, even subtle, should not be overlooked, as well as the introduction of fludrocortisone in isolated hypoaldosteronism and discontinuation of iatrogenic drugs.
Collapse
Affiliation(s)
- Marie-Christine Vantyghem
- Service d'endocrinologie et maladies métaboliques, hôpital Huriez, centre hospitalier régional universitaire de Lille, 1, rue Polonovski, 59000 Lille, France.
| | | | | | | |
Collapse
|
47
|
Wémeau JL. [Thyroid: model or victim?]. Presse Med 2011; 40:1130-1. [PMID: 22078092 DOI: 10.1016/j.lpm.2011.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2011] [Accepted: 10/04/2011] [Indexed: 10/15/2022] Open
|
48
|
Balavoine AS, Bataille P, Vanhille P, Azar R, Noël C, Asseman P, Soudan B, Wémeau JL, Vantyghem MC. Phenotype-genotype correlation and follow-up in adult patients with hypokalaemia of renal origin suggesting Gitelman syndrome. Eur J Endocrinol 2011; 165:665-73. [PMID: 21753071 DOI: 10.1530/eje-11-0224] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION Gitelman syndrome (GS) is a tubulopathy caused by SLC12A3 gene mutations, which lead to hypokalaemic alkalosis, secondary hyperaldosteronism, hypomagnesaemia and hypocalciuria. AIM The aim of this study was to assess the prevalence of SLC12A3 gene mutations in adult hypokalaemic patients; to compare the phenotype of homozygous, heterozygous and non-mutated patients; and to determine the efficiency of treatment. METHODS Clinical, biological and genetic data were recorded in 26 patients. RESULTS Screening for the SLC12A3 gene detected two mutations in 15 patients (six homozygous and nine compound heterozygous), one mutation in six patients and no mutation in five patients. There was no statistical difference in clinical symptoms at diagnosis between the three groups. Systolic blood pressure tended to be lower in patients with two mutations (P=0.16). Hypertension was unexpectedly detected in four patients. Five patients with two mutated alleles and two with heterozygosity had severe manifestations of GS. Significant differences were observed between the three groups in blood potassium, chloride, magnesium, supine aldosterone, 24 h urine chloride and magnesium levels and in modification of the diet in renal disease. Mean blood potassium levels increased from 2.8 ± 0.3, 3.5 ± 0.5 and 3.2 ± 0.3 before treatment to 3.2 ± 0.5, 3.7 ± 0.6 and 3.7 ± 0.3 mmol/l with treatment in groups with two (P=0.003), one and no mutated alleles respectively. CONCLUSION In adult patients referred for renal hypokalaemia, we confirmed the presence of mutations of the SLC12A3 gene in 80% of cases. GS was more severe in patients with two mutated alleles than in those with one or no mutated alleles. High blood pressure should not rule out the diagnosis, especially in older patients.
Collapse
Affiliation(s)
- A S Balavoine
- Service d'Endocrinologie et Maladies Métaboliques, CHRU de Lille, 59037 Lille Cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Wémeau JL, Sadoul JL, d'Herbomez M, Monpeyssen H, Tramalloni J, Leteurtre E, Borson-Chazot F, Caron P, Carnaille B, Léger J, Do Cao C, Klein M, Raingeard I, Desailloud R, Leenhardt L. [Recommendations of the French Society of Endocrinology for the management of thyroid nodules]. Presse Med 2011; 40:793-826. [PMID: 22232784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Affiliation(s)
- Jean-Louis Wémeau
- Clinique endocrinologique Marc-Linquette, CHRU de Lille, 59037 Lille Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Mékinian A, Ladsous M, Balavoine AS, Carnaille B, Aubert S, Soudan B, Wémeau JL. Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia. Presse Med 2011; 40:309-13. [DOI: 10.1016/j.lpm.2010.10.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2010] [Revised: 09/30/2010] [Accepted: 10/06/2010] [Indexed: 11/28/2022] Open
|